


U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
FORM PTO-1390 (REV 10-94)		20039.1USWO
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Unknown 10/547532
INTERNATIONAL APPLICATION NO. PCT/JP2004/002774	INTERNATIONAL FILING DATE 4 March 2004	PRIORITY DATE CLAIMED 4 March 2003
TITLE OF INVENTION MEDICINAL USE OF MIP-3 $\alpha$ INHIBITOR AND METHOD OF SCREENING BRAIN/NERVE CELL PROTECTIVE AGENT		
APPLICANT(S) FOR DO/EO/US SHINTANI, et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l).</p> <p>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))           <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</li> </ul> </p> <p>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))           <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ul> </p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> A signed oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11. to 16. below concern document(s) or information included:		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Form 1449, references.		
12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.		
14. <input type="checkbox"/> A substitute specification.		
15. <input type="checkbox"/> A change of power of attorney and/or address letter.		
16. <input checked="" type="checkbox"/> Other items or information: Application Data Sheet, paper copy of Sequence Listing (13 pages), electronic copy of Sequence Listing, International Publication Page, Form PCT/ISA/210, PCT Request, Form PCT/IB/301, Form PCT/IB/304, Form PCT/IB/306, Form PCT/IB/308, Form PCT/IB/332		

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Unknown <b>10/547532</b>	INTERNATIONAL APPLICATION NO. PCT/JP2004/002774	ATTORNEY'S DOCKET NUMBER 20039.1USWO	
<b>BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):</b>			
[X] a) Basic National fee.....		\$300.00	
[X] b) Examination fee.....		\$200.00	
[X] c) Search fee.....		\$500.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$1000.00</b>	
[X] Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.			
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	
123 -100 = 23	/50 = 1	X \$250.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	23	-20 = 3	X \$50.00
Independent claims	18	-3 = 15	X \$200.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$360.00	\$
<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$4400.00</b>	
Reduction by 1/2 for filing by small entity, if applicable. Small entity status is claimed pursuant to 37 CFR 1.27		\$	
<b>SUBTOTAL =</b>		<b>\$4400.00</b>	
Processing fee of \$130.00 for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+	\$
<b>TOTAL NATIONAL FEE =</b>		<b>\$4400.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+	\$40.00
<b>TOTAL FEES ENCLOSED =</b>		<b>\$4440.00</b>	
		Amount to be: refunded	\$
		charged	\$
<p>a. <input checked="" type="checkbox"/> Check(s) in the amount of <u>\$4400</u> and <u>\$40</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge the amount of \$ to cover the required filing fee for a large entity to the credit card listed on the enclosed credit card authorization form.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-3478.</p>			
<p><b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b></p>			
SEND ALL CORRESPONDENCE TO: Douglas P. Mueller Hamre, Schumann, Mueller & Larson, P.C. P.O. Box 2902-0902 Minneapolis, MN 55402		 SIGNATURE: _____ NAME: Douglas P. Mueller REGISTRATION NUMBER: 30,300	

## UNITED STATES PATENT AND TRADEMARK OFFICE

10/547532

Applicant: SHINTANI, et al.  
 Attorney Docket: 20039.0001USWO  
 Title: MEDICINAL USE OF MIP-3 $\alpha$  INHIBITOR AND METHOD OF  
 SCREENING BRAIN/NERVE CELL PROTECTIVE AGENT

## CERTIFICATE UNDER 37 CFR 1.10

Express Mail mailing label number: EV 648465455 US

Date of Deposit: August 31, 2005

I hereby certify that the papers listed below are being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 CFR 1.10 in an envelope addressed to: Mail Stop Application, Commissioner for Patents, P.O. Box 1450, Arlington, VA 22313-1450.

By: 

Name: Ralynn Wilhelm

Mail Stop PCT  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

52835

PATENT TRADEMARK OFFICE

Sir:

The following papers are transmitted herewith:


- Transmittal sheet, in duplicate, containing Certificate Under 37 CFR 1.10;
- National Stage Patent Application including: Description - 113 pages; Claims - 5 pages; Abstract - 1 page; Drawings - 4 sheets (formal);
- Signed Combined Declaration and Power of Attorney;
- Assignment of the invention to Takeda Pharmaceutical Company Limited, Recordation Form Cover Sheet, a check for \$40.00 to cover the Assignment Recording Fee.
- Application Data Sheet - 5 pages;
- Check(s) for the amount of \$4400 to cover the filing fee calculated below;
- Computer readable form of a Sequence Listing. Applicants state that the paper copy form of the Sequence Listing section of the present application, and the computer readable form submitted herewith, are the same.
- Other: Form PTO-1390, paper copy of Sequence Listing (13 pages), Preliminary Amendment, International Publication Page, Form PCT/ISA/210, PCT Request, Form PCT/IB/301, Form PCT/IB/304, Form PCT/IB/306, Form PCT/IB/308, Form PCT/IB/332
- Return postcard

## CLAIMS AS FILED

Number of Claims Filed	No.	In Excess of	Extra	Rate		Fee
<b>Total Claims</b>	23	20	3	50.00	=	150.00
<b>Independent Claims</b>	18	3	15	200.00	=	3000.00
<b>Multiple Dependent Claims Fee</b>					=	0.00
<b>Basic Filing Fee</b>					=	300.00
<b>Search Fee</b>					=	500.00
<b>Examination Fee</b>					=	200.00
<b>Utility Application Size Fee</b>	123	100	1	250.00	=	250.00
<b>Total</b>					=	4400.00

Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. A duplicate of this sheet is enclosed.

Hamre, Schumann, Mueller & Larson, P.C.  
 P.O. Box 2902-0902 Minneapolis, MN 55402  
 612.455-3800

By:   
 Name: Douglas P. Mueller  
 Reg. No.: 30,300  
 Initials: DPM/pjk